Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 5 March 1982:
Vol. 215. no. 4537, p. 1187
DOI: 10.1126/science.215.4537.1187-a
Prev | Table of Contents | Next

Articles

Correction

An article reporting a congressional hearing on the National Cancer Institute (NCI) (News and Comment, 20 Nov., p. 887) incorrectly states that the institute allowed an unnamed individual to produce a preparation called "Jim's Juice" under what is known as a "compassionate investigational new drug" permit. The NCI, which does not have authority to issue such IND's, was not involved in the matter.

The article also refers to an internal memo written by an NCI researcher about the alleged misuse of an experimental drug called Mitoxantrone. The drug in question was one known as M-AMSA, a new agent against acute leukemia.

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)